Therapeutic vaccines explored in patients with non-small cell lung cancer.
Traditional anti-cancer therapies (surgery, radiotherapy and chemotherapy) have limited effectiveness in curbing progression of advanced tumors. However, with advances in immunology and molecular biology in the last two decades, the prognosis of cancer immunotherapy has improved. An emerging therapy is the cancer vaccine as adjunctive therapy. The purpose of this paper is to review this therapeutic modality for non-small cell lung cancer.
Kui
K
Ma
LSU Health Sciences Center, School of Medicine, 1501 Kings Hwy, P.O. Box 33932, Shreveport, LA 71130, USA. yahuitang2001@yahoo.fr.
Ya H
YH
Tang
D000951:Antigens, Neoplasm / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D004815:Epidermal Growth Factor / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D018396:Mucin-1 / Q000276:immunology; D051193:Toll-Like Receptors / Q000819:agonists
D000951:Antigens, Neoplasm; D001428:Bacterial Vaccines; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines; D018396:Mucin-1; D051193:Toll-Like Receptors; D004815:Epidermal Growth Factor